Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Participants With Multiple Myeloma or Myelofibrosis
Sponsor: University of Utah
Terminated
Slow accrual
Other terminated trials from University of Utah
Listed as NCT03303950, this PHASE2 trial focuses on ASXL1 Gene Mutation and Anemia and remains terminated or withdrawn. Sponsored by University of Utah, it has been updated 14 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 9 earlier versions
-
Nov 2021 — Jun 2022 [monthly]
Terminated PHASE2
-
Apr 2021 — Nov 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Terminated PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2019 — Jun 2020 [monthly]
Recruiting PHASE2
-
Sep 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .